AAP
BCRX icon

Ardsley Advisory Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ardsley Advisory Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,000
Closed -$90K – 173
2015
Q1 		$90K Buy
+10,000
New +$104K 0.01% 184

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ardsley Advisory Partners's BCRX Position: Q2 2015 in Review

Ardsley Advisory Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2015, closing a stake of 10,000 shares — an estimated $90K sold.

Ardsley Advisory Partners first reported a position in BCRX in Q1 2015 and held it in 1 quarter. The position peaked at $90K in Q1 2015. 123 funds tracked by Wall St. Rank hold BCRX as of Q2 2015.

  • Ardsley Advisory Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Ardsley Advisory Partners sold 10,000 BioCryst Pharmaceuticals shares in Q2 2015, an estimated $90K.
  • Ardsley Advisory Partners first reported a position in BioCryst Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Ardsley Advisory Partners's BioCryst Pharmaceuticals position peaked at $90K in Q1 2015.
  • 123 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2015.

Based on Ardsley Advisory Partners's 13F filing for Q2 2015, filed 14 Aug 2015.